CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Eurofarma Laboratorios S.A. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Eurofarma Laboratorios S.A.
Av. Vereador Jos Diniz 3.465
Phone: +1150908600p:+1150908600 Sao Paulo, SP  04603-003  Brazil

Business Summary
Eurofarma Laboratórios S.A., founded in 1972, is a pharmaceutical company. The Company manufactures and markets a broad range of products for human and veterinary use. It also holds licenses and partnerships for the promotion and marketing of third party products. The Company operates more than 10 manufacturing plants.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
---Yes-Yes-

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
--Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations

Subsidiaries
Business Name Address City State/Province Country
Genfar S.A. Transversal 23 No. 97-73 Bogota Colombia

Business Names
Business Name
EUROFARMA LABORATORIOS LTDA
Eurofarma Laboratorios S/A
Genfar S.A.


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 7, 2024